Indeed, clinical, paraclinical, and other laboratory findings resemble those of Caspr1-AN, with half of the patients initially diagnosed as GBS, with ataxia, cranial nerve involvement, and neuropathic pain. The gene discussed is CNTNAP1; the disease is Guillain-Barre syndrome.